Hypoglycemia during Short-Term Intensive Insulin Therapy and Its Association with Long-Term Glycemic Remission in Patients with Newly Diagnosed Type 2 Diabetes
Table 2
Differences between the remission group and the nonremission group during and after CSII cessation.
Remission group
Nonremission group
or value
value
After CSII treatment
BMI decrease (kg/m2)
0.769
0.443
HbA1c (%) (mmol/mol)
-0.494
0.622
FPG (mmol/L)
-3.626
<0.001
PPG (mmol/L)
-3.861
<0.001
Triglyceride (mmol/L)
-1.704
0.090
Cholesterol (mmol/L)
-0.943
0.347
HDL-C (mmol/L)
-0.639
0.524
LDL-C (mmol/L)
0.436
0.663
hsCRP (mg/L)
1.37 (3.01)
1.28 (1.71)
0.256
0.798
AIR (pmol/L10 min)
491.35 (801.89)
370.22 (542.29)
2.191
0.028
HOMA-B
65.00 (73.70)
65.05 (66.86)
1.250
0.211
HOMA-IR
2.08 (2.04)
2.48 (2.32)
2.074
0.038
During CSII treatment
Mean insulin dose (IU/kg)
-2.499
0.013
Mean insulin dose during insulin increase stage (IU/kg)
0.423
0.673
Mean insulin dose during insulin decrease stage (IU/kg)
-1.466
0.144
Mild hypoglycemic episodes per day (3.0~3.9 mmol/L)
0.26 (0.16)
0.11 (0.16)
3.518
<0.001
2.824
0.005
Moderate hypoglycemic episodes per day (<3.0 mmol/L)
0 (0.05)
0 (0.05)
1.097
0.273
-1.228
0.221
Mild hypoglycemia episodes per day during insulin increase stage
0 (0.08)
0 (0.07)
0.094
0.925
-1.290
0.118
Mild hypoglycemia episodes per day during insulin decrease stage
0.29 (0.46)
0.13 (0.30)
2.974
0.003
2.820
0.006
means . BMI: body mass index; HbA1c: glycated hemoglobin; FPG: fasting plasma glucose; PPG: postprandial plasma glucose; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; hsCRP: high-sensitivity C-reactive protein; AIR: acute insulin response; HOMA-B: homeostasis model assessment of β-cell function; HOMA-IR: homeostasis model assessment of insulin resistance.
